PEG-asparaginase during two treatment courses in the treatment of childhood acute lymphoblastic leukemia (Användande av PEG-asparaginase under två behandlingsomgångar vid behandling av akut lymfatisk leukemi hos barn)
- Conditions
- Acute lymphoblastic leukemia in children.
- Registration Number
- EUCTR2005-000658-56-SE
- Lead Sponsor
- Deparment of pediatrics, Skejby Hospital, Denmark
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 85
Inclusion Criteria
Ålder 1-14 år.
Nydiagnosticerad akut lymfatisk leukemi (ALL) behandlad enligt det Nordiska leukemiprotokollet för ALL med ogynnsamma riskfaktorer (NOPHO-ALL 2000).
Behandlas på barnonkologiskt center i Norden
Informerat samtycke givet och påskrivet av vårdnadshavare
Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Allergi mot PEG-asparaginase.
Pancreatit akut eller tidigare genomgången.
Graviditet
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method